Biocept, Inc. (BIOC)
(Delayed Data from NSDQ)
$0.91 USD
+0.01 (1.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.91 USD
+0.01 (1.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Assure Holdings Corp. (IONM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -28.57% and 17.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agiliti (AGTI) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Agiliti (AGTI) delivered earnings and revenue surprises of 5.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 4.55% and 1.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 0.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Misses Q2 Earnings Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 46.15% and 17.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
by Zacks Equity Research
Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.
Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
What Makes Biocept (BIOC) a New Buy Stock
by Zacks Equity Research
Biocept (BIOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biocept (BIOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Biocept (BIOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session
by Zacks Equity Research
Biocept (BIOC) was a big mover last session, as the company saw its shares rise more than 9% on Friday amid huge volumes.
5 Medtech Stocks to Steer Clear of Amid Political Chaos
by Zacks Equity Research
In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.
Teladoc November Visits Set Record: Why is Stock Suffering?
by Zacks Equity Research
Teladoc Inc. (TDOC), the first and the largest telehealth company disclosed that the month of November witnessed a total of 101,600 patient visits.